The indispensable role of pharmacy services and medication therapy management in cystic fibrosis

Grant, Jonathan J.; McDade, Erin; Zobell, Jeffery T.; Young, David C.

doi:10.1002/ppul.25613

Cited by 5 publications

(17 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Haywood and Goralski which found that 59% (51/92) of PwCF at their CF center did not have an identified primary care physician (PCP) or had the CF provider listed as the PCP. 18 Over the years, pharmacists and pharmacy technicians have been expanding their involvement as part of CF care teams and are now recognized as recommended or dedicated members of CF care teams in Europe, the United Kingdom (UK), Australia, and the U.S. [3][4][5][6][7][8] With this expansion of involvement, integrated pharmacy teams (pharmacists and pharmacy technicians) have established many roles as part of those CF care teams. 6,7 One role that has not been recognized previously is administration of immunizations by pharmacy team members.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Implementation of a comprehensive pharmacy‐driven immunization care process model in a pediatric cystic fibrosis clinic

Zobell

Moss

Creelman

et al. 2023

Pediatric Pulmonology

Self Cite

View full text Add to dashboard Cite

Introduction: Members of an integrated pharmacy team (pharmacists and pharmacy technicians) have roles that have been identified in the literature as part of the multi-disciplinary cystic fibrosis (CF) care team. One role that has not specifically addressed is the administration of routine and recommended immunizations to people with CF (PwCF). According to care guidelines, PwCF of all ages should be provided all age-appropriate and recommended immunizations. Pharmacists and pharmacy technicians can administer immunizations per state laws. The Primary Children's CF Center decided to implement a comprehensive pharmacy-driven immunization care process model to impact immunization rates. Methods: A 24-month retrospective analysis was conducted with pediatric (≤18 years) PwCF at the Primary Children's CF Center. The primary outcome measures were the percentage (%) of PwCF who received PPSV23, and/or HPV, and/or meningococcal conjugate vaccine (MCV) immunizations 1-year post-care process model implementation (October 1, 2021, to September 30, 2022) as compared to baseline values. The secondary outcome measures are the total number of immunizations, the number of each immunization provided, and the financial impact of pharmacy-driven immunization care process model 1-year post-implementation. Results: During the 1-year post-care process model implementation (October 1, 2021, to September 30, 2022), a total of 523 immunizations were provided to 243 pediatric PwCF. The most frequent immunizations provided were PPSV23 (160/523, 31%) and Coronavirus Disease 2019 (COVID-19) (154/523, 29%). The baseline percentages of eligible PwCF of PPSV23, HPV, and MCV were 27% (58/217), 43%(32/74), and 24% (8/34), respectively. The 1-year post-implementation percentages of PPSV23, HPV, and MCV were 99% (217/218, p < 0.00001), 91% (67/74, p < 0.00001), and 97% (33/34, p < 0.00001), respectively. For COVID-19 immunizations, 56% of eligible PwCF (181/321) have received their first dose. Of these 181 PwCF, 70% (126/181) have received at least one dose of their primary series or

show abstract

Section: Discussionmentioning

confidence: 99%

“…Recently published literature has highlighted the roles of the integrated pharmacy team in the care of PwCF and the established care process model of the integrated pharmacy team 6,7 . One role that was not specifically addressed was the administration of routine and recommended immunizations to PwCF.…”

Section: Introductionmentioning

confidence: 99%

Implementation of a comprehensive pharmacy‐driven immunization care process model in a pediatric cystic fibrosis clinic

Zobell

Moss

Creelman

et al. 2023

Pediatric Pulmonology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the 2022 Remaining Barriers to Normalcy in Cystic Fibrosis VII supplemental edition of this Journal, Grant and colleagues presented a comprehensive review of the role that pharmacists and pharmacy technicians play in providing care to people with cystic fibrosis (CF). 1 Pharmacists are recommended team members by the Cystic Fibrosis Foundation for the care of people with CF, and specific duties of pharmacists are outlined in several international CF care center guidelines. Published literature by Zobell et al 2 and Autry and Kuhn 3 demonstrated improvement in patients with CF not only in medication adherence, but also in body weight, body mass index, and decreasing hospitalizations for patients with an integrated pharmacy team.…”

Section: To the Editormentioning

confidence: 99%

Section: To the Editormentioning

confidence: 99%

The role of pharmacy services beyond cystic fibrosis: A case for support in childhood interstitial lung disease

McKinzie

Hagood

Fiorino

et al. 2022

Pediatric Pulmonology

View full text Add to dashboard Cite

“…Involvement of a pharmacy clinician is important, given the complexity and medication toxicity profiles utilized in patients with DLD. There is precedence of the importance of clinical pharmacist involvement in the care of CF, 19 and their involvement is likely to benefit other multidisciplinary clinics such as a RLD program. Although dedicated support may be challenging given the rare nature of these diseases and patients, consideration should be given to including as part of the team a pharmacist who has experience with pulmonary and/or immunosuppressant agents.…”

Section: Defining the “Who”: What Colleagues Will Populate Your “Vill...mentioning

confidence: 99%

Building a pediatric rare lung disease program: It takes a community of villages

Vece

Gower

Davis

et al. 2022

Pediatric Pulmonology

View full text Add to dashboard Cite

Pediatric rare lung disease programs are increasing in number due to an increase in recognition of the diseases, increased clinical and research interest in children's interstitial lung disease, and the expansion of the children's interstitial lung disease research network. Due to this increased interest newly graduated trainees in pediatric pulmonology and other physicians are often starting new programs, which can be daunting. We provide some guidance for new programs based on our experiences. K E Y W O R D S children's interstitial lung disease, pediatric rare lung disease 1 | INTRODUCTION Pediatric pulmonologists have been historically "early adopters" of interdisciplinary care of children with complex, often multisystem disorders. 1 Most pediatric pulmonary groups in academic medical centers and larger community practices have set up formal "subsubspecialty" clinics and programs for disease processes such as aerodigestive or neuromuscular disorders, with dedicated involvement of physicians and other professionals, modeled from the Cystic Fibrosis (CF) Foundation-funded care centers, with the goal of improving education, outreach, patient care, and satisfaction. 2,3 Many of these conditions, including CF, primary ciliary dyskinesia (PCD), and many forms of congenital neuromuscular weakness qualify as rare diseases per the National Organization for Rare Disorders (rarediseases.org). Arguably these dedicated interdisciplinary programs result in improved quality and outcomes, and a better experience for families. 2,4,5 Discussion of what diseases constitute Childhood Interstitial and Rare Lung Diseases (ChILD), other rare lung diseases (RLDs), or pediatric diffuse lung disease (DLD) is complex and beyond the scope of this paper, and the terms are often used interchangeably.Classification schemes and general diagnostic approaches have been developed [6][7][8] and most experts in this area take a broad and fairly inclusive view. The care of children with ChILD has evolved in the last two decades from the domain of a few pioneering "guru" clinicians, imagers, and pathologists known worldwide, to a widespread network of interested clinicians, with national and international patient registries, research networks, published clinical guidelines, as well as family support and advocacy foundations on most continents 6,8,9 ). This level of organization and collaboration has facilitated the first international clinical trial of a novel therapy for some forms of ChILD. 10,11 Recently the US News and World Report ranking system included participation in the ChILD Research Network (ChILDRN) as a metric for its pediatric pulmonology evaluation of Children's Hospitals

show abstract

The indispensable role of pharmacy services and medication therapy management in cystic fibrosis

Cited by 5 publications

References 90 publications

Implementation of a comprehensive pharmacy‐driven immunization care process model in a pediatric cystic fibrosis clinic

Implementation of a comprehensive pharmacy‐driven immunization care process model in a pediatric cystic fibrosis clinic

The role of pharmacy services beyond cystic fibrosis: A case for support in childhood interstitial lung disease

Building a pediatric rare lung disease program: It takes a community of villages

Contact Info

Product

Resources

About